Literature DB >> 9815914

Identification of a novel gene, selectively up-regulated in human carcinomas, using the differential display technique.

O Kocher1, P Cheresh, L F Brown, S W Lee.   

Abstract

Using the differential display technique, selecting for genes up-regulated in renal cell carcinoma compared with normal renal parenchyma, we isolated a novel gene, designated DD96. As determined by in situ and Northern blot hybridization studies, DD96 is expressed only in rare normal epithelial cell populations, such as the proximal tubular epithelial cells of the kidney. However, it is expressed diffusely in malignant epithelial cells of the wide majority of renal cell carcinomas. In addition, DD96 is overexpressed markedly in various human carcinomas originating from the colon, breast, and lung, as well as in a number of cell lines derived from tumors of these organs compared with normal epithelial cell populations. Furthermore, the expression of DD96 is induced in immortalized breast ductal epithelial cell lines compared with normal breast ductal epithelial cells, and, in vivo, in premalignant conditions, such as adenoma of the colon and ductal carcinoma in situ of the breast. Sequence analysis of a complete cDNA clone isolated from a human kidney cDNA library revealed that DD96 encodes for a protein of approximately Mr 13,500. These results suggest that DD96 may play a role in the early events associated with malignant transformation; however, its function remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 9815914

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  13 in total

1.  Identification and partial characterization of a novel membrane-associated protein (MAP17) up-regulated in human carcinomas and modulating cell replication and tumor growth.

Authors:  O Kocher; P Cheresh; S W Lee
Journal:  Am J Pathol       Date:  1996-08       Impact factor: 4.307

Review 2.  Scavenger receptor B type 1: expression, molecular regulation, and cholesterol transport function.

Authors:  Wen-Jun Shen; Shailendra Asthana; Fredric B Kraemer; Salman Azhar
Journal:  J Lipid Res       Date:  2018-05-02       Impact factor: 5.922

3.  Targeted disruption of the PDZK1 gene by homologous recombination.

Authors:  Olivier Kocher; Rinku Pal; Mark Roberts; Christine Cirovic; Annalyn Gilchrist
Journal:  Mol Cell Biol       Date:  2003-02       Impact factor: 4.272

4.  Transcriptome sequencing of malignant pleural mesothelioma tumors.

Authors:  David J Sugarbaker; William G Richards; Gavin J Gordon; Lingsheng Dong; Assunta De Rienzo; Gautam Maulik; Jonathan N Glickman; Lucian R Chirieac; Mor-Li Hartman; Bruce E Taillon; Lei Du; Pascal Bouffard; Stephen F Kingsmore; Neil A Miller; Andrew D Farmer; Roderick V Jensen; Steven R Gullans; Raphael Bueno
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-26       Impact factor: 11.205

5.  MAP17 Is a Necessary Activator of Renal Na+/Glucose Cotransporter SGLT2.

Authors:  Michael J Coady; Abdulah El Tarazi; René Santer; Pierre Bissonnette; Louis J Sasseville; Joaquim Calado; Yoann Lussier; Christopher Dumayne; Daniel G Bichet; Jean-Yves Lapointe
Journal:  J Am Soc Nephrol       Date:  2016-06-10       Impact factor: 10.121

6.  MAP17 contributes to non-small cell lung cancer progression via suppressing miR-27a-3p expression and p38 signaling pathway.

Authors:  Qian Liang; Huan Zhang
Journal:  Cancer Biol Ther       Date:  2020-12-07       Impact factor: 4.742

7.  MAP17, a ROS-dependent oncogene.

Authors:  Amancio Carnero
Journal:  Front Oncol       Date:  2012-09-06       Impact factor: 6.244

8.  The cargo protein MAP17 (PDZK1IP1) regulates the immune microenvironment.

Authors:  José M García-Heredia; Amancio Carnero
Journal:  Oncotarget       Date:  2017-10-06

9.  Impaired in vitro erythropoiesis following deletion of the Scl (Tal1) +40 enhancer is largely compensated for in vivo despite a significant reduction in expression.

Authors:  Rita Ferreira; Dominik Spensberger; Yvonne Silber; Andrew Dimond; Juan Li; Anthony R Green; Berthold Göttgens
Journal:  Mol Cell Biol       Date:  2013-01-14       Impact factor: 4.272

10.  Efficacy of bortezomib in sarcomas with high levels of MAP17 (PDZK1IP1).

Authors:  Marco Perez; Javier Peinado-Serrano; Jose Manuel Garcia-Heredia; Irene Felipe-Abrio; Cristina Tous; Irene Ferrer; Javier Martin-Broto; Carmen Saez; Amancio Carnero
Journal:  Oncotarget       Date:  2016-10-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.